Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. develops targeted oncology therapies for patients with RAS-addicted cancers. Company news centers on its RAS(ON) inhibitor pipeline, including daraxonrasib, a RAS(ON) multi-selective inhibitor, and selective programs such as elironrasib, zoldonrasib and RMC-5127.
Recurring updates cover clinical data in pancreatic ductal adenocarcinoma, non-small cell lung cancer and other RAS-mutant solid tumors, presentations at oncology meetings, scientific publications, regulatory interactions and trial-stage progress. Revolution Medicines also reports quarterly financial results, financing activity and corporate progress tied to research and development, potential commercialization planning and its broader RAS(ON) discovery platform.
BeOne Medicines (Nasdaq: ONC; HKEX: 06160; SSE: 688235) and Revolution Medicines (Nasdaq: RVMD) announced a multi-part collaboration covering clinical development of drug combinations and regional commercialization for RAS-addicted cancers.
The clinical collaboration will evaluate combinations of select BeOne oncology assets, including BGB-58067 (MTA-cooperative PRMT5 inhibitor) and BG-T187 (EGFR x MET x MET trispecific antibody), with any of Revolution Medicines’ four clinical RAS(ON) inhibitors: daraxonrasib (multi-selective), zoldonrasib (G12D-selective), elironrasib (G12C-selective) and RMC-5127 (G12V-selective). Under a separate regional rights agreement, Revolution Medicines granted BeOne exclusive rights in select Asian markets to develop and commercialize, or solely commercialize, these four assets. Revolution Medicines is eligible for development and sales milestones and tiered royalties on net sales, and retains rights outside the licensed territory, including Japan and South Korea. BeOne will fund and conduct a global registrational Phase 3 study for one RAS(ON) inhibitor.
Revolution Medicines (Nasdaq: RVMD) reported second quarter 2026 results and major clinical, regulatory and financing milestones. The U.S. FDA accepted the New Drug Application for daraxonrasib in previously treated metastatic pancreatic cancer, following Phase 3 RASolute 302 data showing significant improvements in survival, progression-free survival and quality of life versus chemotherapy. The EMA began a phased review under its Cancer Medicines Pathfinder project, and Swissmedic granted Orphan Drug Status. An FDA-cleared Expanded Access Program has already enabled daraxonrasib distribution to treating physicians on behalf of more than 2,000 patients across nearly all U.S. states and Puerto Rico.
Daraxonrasib also received FDA Breakthrough Therapy Designation for certain previously treated metastatic RAS mutant NSCLC, and multiple Phase 3 trials in pancreatic and lung cancer are underway or planned. Zoldonrasib and elironrasib combinations in first-line NSCLC showed preliminary overall response rates of 82% and 85%, respectively, with high disease control and manageable safety. Cash, cash equivalents and marketable securities totaled $3.9 billion at June 30, 2026, after $2.225 billion in April equity and convertible note offerings and a $250 million Royalty Pharma payment, though quarterly net loss widened to $644.4 million.
Revolution Medicines (Nasdaq: RVMD) will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after market close. At 4:30 p.m. ET (1:30 p.m. PT), senior management will host a live webcast, with a replay available on the company’s investor relations website for at least 14 days.
Revolution Medicines (Nasdaq: RVMD) reported that the U.S. FDA has accepted for review its New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, to treat adults with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
The NDA is supported by the global Phase 3 RASolute 302 trial comparing daraxonrasib monotherapy with standard cytotoxic chemotherapy. According to Revolution Medicines, the study met all primary and key secondary endpoints, showing improvements in overall survival, progression-free survival, response outcomes, and patient‑reported quality of life, with a manageable safety profile.
Daraxonrasib has FDA Breakthrough Therapy and Orphan Drug designations and was selected for the FDA Commissioner’s National Priority Voucher pilot program. In Europe, the EMA has started a phased review and granted orphan medicine designation and high-priority status under its Cancer Medicines Pathfinder project.
Revolution Medicines (Nasdaq: RVMD) reported that EMA’s CHMP has begun a phased review of daraxonrasib for pancreatic cancer, aiming to accelerate assessment before a full marketing application.
Daraxonrasib has EMA orphan drug status, Cancer Medicines Pathfinder priority, and a rolling NDA submission to the U.S. FDA nearing completion, supported by positive Phase 3 RASolute 302 data.
Revolution Medicines (Nasdaq: RVMD) reported Phase 1/2 data for zoldonrasib combinations in RAS G12D metastatic pancreatic cancer at ESMO GI 2026.
First-line zoldonrasib plus chemotherapy showed ORR up to 82%, while zoldonrasib plus daraxonrasib in pretreated patients showed ORR of 47–50%, supporting pivotal Phase 3 RASolute 305 and 309 trials.
Revolution Medicines (RVMD) will present new clinical data from its RAS(ON) inhibitor combination trials in pancreatic cancer at the ESMO Gastrointestinal Cancers Congress 2026, July 1–4 in Munich.
The program features two Phase 1/2 zoldonrasib combination orals and two Phase 3 RASolute trial posters in PDAC.
Revolution Medicines (RVMD) has begun treating patients in RASolute 305, a global randomized Phase 3 trial of zoldonrasib plus standard chemotherapy as first line treatment for metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC).
The double-blind, placebo-controlled study compares zoldonrasib plus investigator’s choice of modified FOLFIRINOX or gemcitabine plus nab-paclitaxel versus placebo plus chemotherapy. Primary endpoints are progression-free survival and overall survival, with key secondary endpoints including antitumor activity, safety, tolerability, and patient-reported outcomes.
Revolution Medicines (Nasdaq: RVMD) announced a planned leadership transition for Steve Kelsey, M.D., president of R&D. Effective July 1, 2026, he becomes senior advisor to the CEO, with retirement planned for January 4, 2027, and anticipated appointment to the board.
The company will adopt a new R&D leadership structure, with Alan Sandler, M.D. overseeing development, Jan Smith, Ph.D. leading research, and Xiaolin Wang, Sc.D. serving as executive vice president, integrated portfolio strategy and management.
Revolution Medicines (Nasdaq: RVMD) reported pivotal Phase 3 RASolute 302 results for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma.
Daraxonrasib reduced risk of death by 60% (HR 0.40), doubled median OS to 13.2 vs ~6.6–6.7 months, improved PFS and response rates, and showed a generally manageable safety profile versus chemotherapy. The company plans global regulatory filings and has an FDA-authorized expanded access program.